VERIGRAFT Secures $1.2M in Grant Funding to Pioneer Personalized Tissue Engineering and Regenerative Medicine Solutions

We are excited to announce that VERIGRAFT has successfully raised €1,200,000 through our latest funding round, a monumental achievement that marks an important milestone for our innovative company.

VERIGRAFT is at the forefront of regenerative medicine, transforming donated allogeneic tissue into personalized, autologous-like transplants through advanced tissue engineering techniques.

By combining Decellularization (DC) and Reconditioning/Recellularization (RC) processes, we convert allogenic tissue into safe, patient-specific products.

This breakthrough technology not only minimizes risks associated with transplant rejection but also eliminates the necessity for long-term immunosuppression, thereby significantly improving patient outcomes.

The funds we have raised will be pivotal in advancing our development pipeline, particularly in the areas of vascular regeneration and peripheral nerve repair.

With this fresh capital, we plan to accelerate clinical trials, optimize manufacturing processes, and ultimately bring our cutting-edge products closer to regulatory approval and market readiness.

The support from our investors underscores the immense promise of VERIGRAFT’s personalized tissue-engineered transplants and reinforces our commitment to pioneering solutions that transform lives.

In addition, we continue to welcome private individuals to join us through our ongoing crowdfunding campaign.

This unique opportunity to be part of our journey not only democratizes investment in groundbreaking science but also fosters a community of supporters who believe in the future of regenerative medicine.

Further details about the campaign can be found on our website at https://capitalcell.com/en/campaign/verigraft/.

As we forge ahead towards revolutionizing transplant medicine, we remain dedicated to harnessing innovative technologies and partnerships to deliver transformative healthcare solutions.